Preventing COVID-19 with Photodisinfection – New Results Presented at European Society of Photobiology
Retrieved on:
Saturday, September 18, 2021
Norwegian Society for Photobiology and Photomedicine, WHO, Vaccine, Nose, Compliance, Pain, Infection, Genome, Inflammation, Candida auris, Photobiology, Globe, Patient, Disinfectant, Drug of last resort, COVID-19, Hospital, CDC, Bacteria, Virus, CEO, Auris, COVID, Ventilator-associated pneumonia, MRSA, Fungus, Breeding, CE, Sinusitis, Severe acute respiratory syndrome coronavirus 2, Eyeish, Oxidative stress, Research, Incidence, Biofilm, Light, Subclinical infection, Burns, Pharmaceutical industry
[3]
Key Points:
- [3]
Ondine Biomedical, which specializes in photodisinfection-based medical devices, presented in vitro and in vivo results which demonstrated elimination of the SARS-CoV-2 genome after less than a few minutes of photodisinfection treatment at the recent European Society of Photobiology conference in Austria. - Ondines photodisinfection technology was also shown to destroy spike protein and receptor binding domains from various major viral variants including the highly infectious Delta variant from India.
- Dr. Nicolas Loebel, President and Chief Technology Officer, told the meeting, The nose is a major reservoir of SARS-CoV-2.
- Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - bacterial, viral and fungal - including multidrug-resistant strains.